ueec_nt10q.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 12b-25
 
NOTIFICATION OF LATE FILING
 
(Check one): X
 
o Form10K
o
Form 20-F
o
Form 11-K
x
Form 10-Q
o
Form 10-D
o
Form N-SAR
o
Form N-CSR

  For Period Ended: 06/30/2014                                                                     

 
o
Transition Report on Form 10-K
 
o
Transition Report on Form 20-F
 
o
Transition Report on Form 11-K
 
o
Transition Report on Form 10-Q
 
o
Transition Report on Form N-SAR

 
For the Transition Period Ended:____________________________
 
Read Instructions (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
 
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
 
 
PART I — REGISTRANT INFORMATION
 
United Health Products, Inc.
Full Name of Registrant
 
 
Former Name if Applicable
 
c/o Morse & Morse, PLLC, 1400 Old Country Road, Suite 302
Address of Principal Executive Office (Street and Number)
 
Westbury, NY 11590
City, State and Zip Code

 
 
 
 
PART II — RULES 12b-25(b) AND (c)
 
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
 
x
(a)
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
   
(b)
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D,or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
   
(c)
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
 
PART III — NARRATIVE
 
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra Sheets if Needed)
 
Additional time is required to complete the Form 10-Q and the XBRL data and file same.
 
PART IV — OTHER INFORMATION
 
(1)     
Name and telephone number of person to contact in regard to this notification

         
Steven Morse, Esq.
  
(516)
  
487-1446
(Name)
  
(Area Code)
  
(Telephone Number)

(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).  Yes  x      No  o
 
(3)     
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?  Yes  x      No  o
 
     
 
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
 
The Registrant’s estimated net loss for the three months ended June 30, 2014 is $215,680 as compared to $103,087 for the comparable period of the prior year. The net loss for the six months ended June 30, 2014 was $382,042 as compared to $160,318 for the comparable period of the prior year.
 
 
2
 
 
United Health Products, Inc. has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
 
  UNITED HEALTH PRODUCTS, INC.  
       
Date: August 14, 2014
By:
/s/ Douglas Beplate  
    Douglas Beplate  
    Chief Operating Officer  
       
 
 
 
 3